Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PP562: sourced facts only. name: "These results suggested that PP562 might exert its inhibitory effect on HCG-27 proliferation through the DDR2 target." [PMID:37030105]; target: "These results suggested that PP562 might exert its inhibitory effect on HCG-27 proliferation through the DDR2 target." [PMID:37030105]; developer: "State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization and the Key Laboratory of Plant Resources in Arid Regions, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, 40-1 South Beijing Rd, Urumqi 830011, China; University of Chinese Academy of Sciences, Yuquan Rd 19 A, Beijing 100049, China." [PMID:37030105]; stage: "PP562 also exhibits excellent anticancer potency toward the HGC-27 gastric cancer cell line." [PMID:37030105]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PP562.